Published in Int J Microbiol on February 03, 2013
Effective removal of staphylococcal biofilms by the endolysin LysH5. PLoS One (2014) 0.90
Investigation of biofilm forming ability in Staphylococci causing bovine mastitis using phenotypic and genotypic assays. ScientificWorldJournal (2013) 0.84
Control of Bovine Mastitis: Old and Recent Therapeutic Approaches. Curr Microbiol (2015) 0.80
Bacteriophages as Weapons Against Bacterial Biofilms in the Food Industry. Front Microbiol (2016) 0.78
Monitoring in Real Time the Formation and Removal of Biofilms from Clinical Related Pathogens Using an Impedance-Based Technology. PLoS One (2016) 0.77
Crystallization of the CHAP domain of the endolysin from Staphylococcus aureus bacteriophage K. Acta Crystallogr Sect F Struct Biol Cryst Commun (2013) 0.77
Crystal structure of the lytic CHAP(K) domain of the endolysin LysK from Staphylococcus aureus bacteriophage K. Virol J (2014) 0.77
New Weapons to Fight Old Enemies: Novel Strategies for the (Bio)control of Bacterial Biofilms in the Food Industry. Front Microbiol (2016) 0.75
Thermally triggered release of the bacteriophage endolysin CHAPK and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA). J Control Release (2016) 0.75
Analysis of Shigella flexneri Resistance, Biofilm Formation, and Transcriptional Profile in Response to Bile Salts. Infect Immun (2017) 0.75
Bacterial biofilms: a common cause of persistent infections. Science (1999) 40.82
Staphylococcus aureus infections. N Engl J Med (1998) 36.39
Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev (2002) 17.58
Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev (1997) 12.33
Bacteriophage resistance mechanisms. Nat Rev Microbiol (2010) 7.38
The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol (1999) 7.19
A bacteriolytic agent that detects and kills Bacillus anthracis. Nature (2002) 5.63
Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest (2003) 5.33
Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science (2001) 3.72
Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev (2002) 3.62
Mechanisms of antibiotic resistance in bacterial biofilms. Int J Med Microbiol (2002) 3.57
Staphylococcal resistance revisited: community-acquired methicillin resistant Staphylococcus aureus--an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis (2003) 2.92
Bacteriophage endolysins--current state of research and applications. Curr Opin Microbiol (2005) 2.85
Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol (2005) 2.55
Significance of microbial biofilms in food industry: a review. Int J Food Microbiol (1998) 2.50
Direct continuous method for monitoring biofilm infection in a mouse model. Infect Immun (2003) 2.35
Bacteriophage endolysins: a novel anti-infective to control Gram-positive pathogens. Int J Med Microbiol (2010) 2.31
Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol (2002) 2.24
Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res (2002) 2.20
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol (2004) 1.91
Biofilms: a role in recurrent mastitis infections? Vet J (2006) 1.77
Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces. Antimicrob Agents Chemother (2003) 1.69
Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol (2004) 1.67
The recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureus. J Bacteriol (2005) 1.63
Lytic activity of recombinant bacteriophage phi11 and phi12 endolysins on whole cells and biofilms of Staphylococcus aureus. Appl Environ Microbiol (2006) 1.62
Efficient elimination of multidrug-resistant Staphylococcus aureus by cloned lysin derived from bacteriophage phi MR11. J Infect Dis (2007) 1.61
Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection. Antimicrob Agents Chemother (2003) 1.56
A mouse model of post-arthroplasty Staphylococcus aureus joint infection to evaluate in vivo the efficacy of antimicrobial implant coatings. PLoS One (2010) 1.52
Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial. Br J Dermatol (2006) 1.47
Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against Staphylococcus aureus in milk. Int J Food Microbiol (2008) 1.36
Resistance of bacterial biofilms to disinfectants: a review. Biofouling (2011) 1.34
Bacteriophage-resistance systems in dairy starter strains: molecular analysis to application. Antonie Van Leeuwenhoek (2002) 1.34
Endolysins as antimicrobials. Adv Virus Res (2012) 1.33
LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiol Lett (2008) 1.30
A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother (2010) 1.29
Noninvasive optical imaging method to evaluate postantibiotic effects on biofilm infection in vivo. Antimicrob Agents Chemother (2004) 1.26
Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl Environ Microbiol (2008) 1.26
Bovine mastitis and intramammary drug delivery: review and perspectives. Adv Drug Deliv Rev (2001) 1.23
Chimeric phage lysins act synergistically with lysostaphin to kill mastitis-causing Staphylococcus aureus in murine mammary glands. Appl Environ Microbiol (2012) 1.15
Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs (2011) 1.13
Novel method to control pathogenic bacteria on human mucous membranes. Ann N Y Acad Sci (2003) 1.11
LysGH15, a novel bacteriophage lysin, protects a murine bacteremia model efficiently against lethal methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol (2010) 1.07
Incidence of Staphylococcus aureus and analysis of associated bacterial communities on food industry surfaces. Appl Environ Microbiol (2012) 1.07
Inhibition of bacteriophage K proliferation on Staphylococcus aureus in raw bovine milk. Lett Appl Microbiol (2005) 1.05
Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme. Appl Microbiol Biotechnol (2009) 1.02
Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit Rev Microbiol (2012) 1.02
Biofilms: microbes and disease. Braz J Infect Dis (2008) 1.02
Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol (2009) 0.99
Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus. Appl Microbiol Biotechnol (2012) 0.96
In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin. Antimicrob Agents Chemother (2011) 0.96
Occurrence of enterotoxigenic Staphylococcus aureus in food. Ann Agric Environ Med (2002) 0.96
The truncated phage lysin CHAP(k) eliminates Staphylococcus aureus in the nares of mice. Bioeng Bugs (2011) 0.94
Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives. Lett Appl Microbiol (2012) 0.92
Characterization of the staphylococcal bacteriophage lysin CHAP(K). J Appl Microbiol (2011) 0.89
Use of a bacteriophage lysin, PlyC, as an enzyme disinfectant against Streptococcus equi. Appl Environ Microbiol (2009) 0.88
Antimicrobial coating agents: can biofilm formation on a breast implant be prevented? J Plast Reconstr Aesthet Surg (2008) 0.87
Adhesion and detachment kinetics of several strains of Staphylococcus aureus subsp. aureus under three different experimental conditions. Food Microbiol (2007) 0.87
Surface coating strategies to prevent biofilm formation on implant surfaces. Int J Artif Organs (2010) 0.86
Comparison of the antibacterial properties of phage endolysins SAL-1 and LysK. Antimicrob Agents Chemother (2011) 0.84
Microbial contamination of carcasses, meat, and equipment from an Iberian pork cutting plant. J Food Prot (2004) 0.83
Gut microbiota composition correlates with diet and health in the elderly. Nature (2012) 6.94
Bacteriocins: developing innate immunity for food. Nat Rev Microbiol (2005) 5.77
Ribosomally synthesized and post-translationally modified peptide natural products: overview and recommendations for a universal nomenclature. Nat Prod Rep (2013) 5.38
Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci U S A (2010) 5.02
Comparative analysis of pyrosequencing and a phylogenetic microarray for exploring microbial community structures in the human distal intestine. PLoS One (2009) 4.93
Complete genome sequence of the probiotic lactic acid bacterium Lactobacillus acidophilus NCFM. Proc Natl Acad Sci U S A (2005) 4.46
Comparison of two next-generation sequencing technologies for resolving highly complex microbiota composition using tandem variable 16S rRNA gene regions. Nucleic Acids Res (2010) 4.17
Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev (2010) 3.30
Bacteriocins - a viable alternative to antibiotics? Nat Rev Microbiol (2012) 2.76
Bacterial lantibiotics: strategies to improve therapeutic potential. Curr Protein Pept Sci (2005) 2.21
Genome sequence of Lactobacillus helveticus, an organism distinguished by selective gene loss and insertion sequence element expansion. J Bacteriol (2007) 2.15
Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A (2010) 2.11
Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc Natl Acad Sci U S A (2010) 1.89
The mycobacteria story in Crohn's disease. Am J Gastroenterol (2005) 1.71
High-throughput sequencing reveals the incomplete, short-term recovery of infant gut microbiota following parenteral antibiotic treatment with ampicillin and gentamicin. Antimicrob Agents Chemother (2012) 1.69
Identification of a novel two-peptide lantibiotic, lichenicidin, following rational genome mining for LanM proteins. Appl Environ Microbiol (2009) 1.68
The generation of nisin variants with enhanced activity against specific gram-positive pathogens. Mol Microbiol (2008) 1.62
Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry (2004) 1.61
Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio (2012) 1.59
Bacteriocin production: a probiotic trait? Appl Environ Microbiol (2011) 1.57
Listeriolysin S, a novel peptide haemolysin associated with a subset of lineage I Listeria monocytogenes. PLoS Pathog (2008) 1.53
Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev (2009) 1.48
Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol (2010) 1.48
Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol (2006) 1.45
Streptolysin S-like virulence factors: the continuing sagA. Nat Rev Microbiol (2011) 1.42
Microarray analysis of a two-component regulatory system involved in acid resistance and proteolytic activity in Lactobacillus acidophilus. Appl Environ Microbiol (2005) 1.41
A five-strain probiotic combination reduces pathogen shedding and alleviates disease signs in pigs challenged with Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol (2007) 1.38
Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases. Mar Drugs (2011) 1.36
Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol (2011) 1.34
Bacteriophage-resistance systems in dairy starter strains: molecular analysis to application. Antonie Van Leeuwenhoek (2002) 1.34
Antimicrobial activity of lacticin 3,147 against clinical Clostridium difficile strains. J Med Microbiol (2007) 1.33
Isolation and analysis of bacteria with antimicrobial activities from the marine sponge Haliclona simulans collected from Irish waters. Mar Biotechnol (NY) (2008) 1.30
Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother (2005) 1.30
Discovery of medically significant lantibiotics. Curr Drug Discov Technol (2009) 1.29
Mycobacterium avium subsp. Paratuberculosis (MAP) as a modifying factor in Crohn's disease. Inflamm Bowel Dis (2010) 1.27
Two-peptide lantibiotics: a medical perspective. Mini Rev Med Chem (2007) 1.26
Phage lysin LysK can be truncated to its CHAP domain and retain lytic activity against live antibiotic-resistant staphylococci. Appl Environ Microbiol (2008) 1.26
Comparative genomics of lactic acid bacteria reveals a niche-specific gene set. BMC Microbiol (2009) 1.24
Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps. Gut Microbes (2012) 1.23
High-throughput sequencing for detection of subpopulations of bacteria not previously associated with artisanal cheeses. Appl Environ Microbiol (2012) 1.23
Lantibiotic immunity. Curr Protein Pept Sci (2008) 1.22
Contribution of penicillin-binding protein homologs to antibiotic resistance, cell morphology, and virulence of Listeria monocytogenes EGDe. Antimicrob Agents Chemother (2006) 1.21
Identification of a novel two-peptide lantibiotic, haloduracin, produced by the alkaliphile Bacillus halodurans C-125. FEMS Microbiol Lett (2007) 1.21
Posttranslational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic lacticin 3147. Proc Natl Acad Sci U S A (2005) 1.20
A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother (2009) 1.20
Relative ability of orally administered Lactobacillus murinus to predominate and persist in the porcine gastrointestinal tract. Appl Environ Microbiol (2004) 1.18
The dawning of a 'Golden era' in lantibiotic bioengineering. Mol Microbiol (2010) 1.18
The complex microbiota of raw milk. FEMS Microbiol Rev (2013) 1.18
The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol (2009) 1.16
Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. Am J Clin Nutr (2009) 1.15
Studies with bioengineered Nisin peptides highlight the broad-spectrum potency of Nisin V. Microb Biotechnol (2010) 1.14
Production of the Bsa lantibiotic by community-acquired Staphylococcus aureus strains. J Bacteriol (2009) 1.13
Recombinant bacteriophage lysins as antibacterials. Bioeng Bugs (2011) 1.13
Recommendations for the viability assessment of probiotics as concentrated cultures and in food matrices. Int J Food Microbiol (2011) 1.13
Production of bioactive substances by intestinal bacteria as a basis for explaining probiotic mechanisms: bacteriocins and conjugated linoleic acid. Int J Food Microbiol (2011) 1.11
Fermented functional foods based on probiotics and their biogenic metabolites. Curr Opin Biotechnol (2005) 1.10
Characterization of pro-inflammatory flagellin proteins produced by Lactobacillus ruminis and related motile Lactobacilli. PLoS One (2012) 1.09
Putting microbes to work: dairy fermentation, cell factories and bioactive peptides. Part II: bioactive peptide functions. Biotechnol J (2007) 1.09
Bacteriophages as biocontrol agents of food pathogens. Curr Opin Biotechnol (2010) 1.09
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics. Antimicrob Agents Chemother (2010) 1.09
Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens. PLoS One (2012) 1.08
The impact of antibiotics on the gut microbiota as revealed by high throughput DNA sequencing. Discov Med (2012) 1.08
Production of enterolysin A by a raw milk enterococcal isolate exhibiting multiple virulence factors. Microbiology (2003) 1.08
The health promoting properties of the conjugated isomers of α-linolenic acid. Lipids (2010) 1.08
Sequencing-based analysis of the bacterial and fungal composition of kefir grains and milks from multiple sources. PLoS One (2013) 1.07
Bacterial neuroactive compounds produced by psychobiotics. Adv Exp Med Biol (2014) 1.06
Phage therapy in the food industry. Annu Rev Food Sci Technol (2014) 1.06
Movers and shakers: influence of bacteriophages in shaping the mammalian gut microbiota. Gut Microbes (2012) 1.06
Association of beta-glucan endogenous production with increased stress tolerance of intestinal lactobacilli. Appl Environ Microbiol (2009) 1.05
TelA contributes to the innate resistance of Listeria monocytogenes to nisin and other cell wall-acting antibiotics. Antimicrob Agents Chemother (2010) 1.05
Tolerance of Listeria monocytogenes to cell envelope-acting antimicrobial agents is dependent on SigB. Appl Environ Microbiol (2006) 1.05
Molecular approaches to analysing the microbial composition of raw milk and raw milk cheese. Int J Food Microbiol (2011) 1.05
In silico analysis highlights the frequency and diversity of type 1 lantibiotic gene clusters in genome sequenced bacteria. BMC Genomics (2010) 1.04
Genome analysis of the Clostridium difficile phage PhiCD6356, a temperate phage of the Siphoviridae family. Gene (2010) 1.04
The α-amylase and α-glucosidase inhibitory effects of Irish seaweed extracts. Food Chem (2013) 1.03
Sequence-based analysis of the bacterial and fungal compositions of multiple kombucha (tea fungus) samples. Food Microbiol (2013) 1.02
Microbial composition of human appendices from patients following appendectomy. MBio (2013) 1.02
Genome mining for radical SAM protein determinants reveals multiple sactibiotic-like gene clusters. PLoS One (2011) 1.01
The microbial content of raw and pasteurized cow milk as determined by molecular approaches. J Dairy Sci (2013) 1.01
Targeting the microbiota to address diet-induced obesity: a time dependent challenge. PLoS One (2013) 1.01
Effect of Lactobacillus salivarius bacteriocin Abp118 on the mouse and pig intestinal microbiota. PLoS One (2012) 1.00
Cross-immunity and immune mimicry as mechanisms of resistance to the lantibiotic lacticin 3147. Mol Microbiol (2009) 1.00
Effects of short-term feeding of Bt MON810 maize on growth performance, organ morphology and function in pigs. Br J Nutr (2011) 1.00